MedTrace Logo

A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil

NCT02392273 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-12-28

No results posted yet for this study

Summary

This study is an observational study with the primary objective to assess the safety and tolerability of Ausanil in the treatment of primary headache disorders. The secondary objective is to assess headache pain, functional outcome, time loss to headache and patient satisfaction with Ausanil treatment.

Conditions

  • Primary Headache Disorders

Interventions

DRUG

Ausanil

Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.

Sponsors & Collaborators

  • VR1 Corporation

    lead INDUSTRY

Principal Investigators

  • Seth Stoller, MD · Atlantic Health System

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02392273 on ClinicalTrials.gov